Amendment: SEC Form SC 13G/A filed by MultiPlan Corporation
$MPLN
Business Services
Consumer Discretionary
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/26/2024 | $2.00 | Neutral | Piper Sandler |
| 12/13/2022 | $3.00 → $2.00 | Buy → Neutral | Citigroup |
| 7/12/2022 | $6.50 | Neutral | Goldman |
| 12/20/2021 | $9.00 → $7.00 | Buy | Citigroup |
| 11/11/2021 | $7.00 → $6.00 | Equal-Weight | Barclays |
| 10/4/2021 | $9.00 | Buy | Citigroup |
| 8/20/2021 | $9.00 | Buy | Tigress Financial |
– Q3 2024 Revenues of $230.5 million, Net Loss of $391.5 million (including a $361.6 million impairment of goodwill and indefinite-lived intangibles), and Adjusted EBITDA of $141.6 million – Identified potential medical cost savings of approximately $6.4 billion in Q3 2024, up 10% from Q3 2023 and up 3% from Q2 2024 MultiPlan Corporation ("MultiPlan" or the "Company") (NYSE:MPLN), a leading provider of data-driven cost management solutions that deliver transparency and promote fairness, quality and affordability to the U.S. healthcare industry, today reported financial results for the third quarter ended September 30, 2024 and updated its full-year 2024 guidance. CEO Travis Dalton said,
MultiPlan Corporation (NYSE:MPLN), a leading provider of data-driven cost management solutions that deliver transparency and promote fairness, quality and affordability to the U.S. healthcare industry, is accepting applications for its Rural Health Grant now through December 15, 2024 from rural healthcare providers in the U.S. The grants provide financial resources to introduce or expand services, education, screenings and other programs aimed at improving the health of people in their communities. The MultiPlan Rural Health Grant is available to hospitals, rural health clinics and federally qualified health centers participating in any of MultiPlan's healthcare provider networks, includin
Tiffani Misencik Named Chief Growth Officer in New Executive Leadership Role MultiPlan Corporation ("MultiPlan" or the "Company") (NYSE:MPLN), a leading provider of data-driven cost management solutions that deliver transparency and promote fairness, quality and affordability to the U.S. healthcare industry, today announced a new addition to its executive leadership team to support the next phase of the Company's strategic growth. Tiffani Misencik has been appointed Chief Growth Officer. In this newly created role, Misencik will oversee MultiPlan's sales and revenue growth strategy across all market segments. She will lead the company's efforts in client acquisition, client management, an
4 - MultiPlan Corp (0001793229) (Issuer)
4 - MultiPlan Corp (0001793229) (Issuer)
4 - MultiPlan Corp (0001793229) (Issuer)
Tiffani Misencik Named Chief Growth Officer in New Executive Leadership Role MultiPlan Corporation ("MultiPlan" or the "Company") (NYSE:MPLN), a leading provider of data-driven cost management solutions that deliver transparency and promote fairness, quality and affordability to the U.S. healthcare industry, today announced a new addition to its executive leadership team to support the next phase of the Company's strategic growth. Tiffani Misencik has been appointed Chief Growth Officer. In this newly created role, Misencik will oversee MultiPlan's sales and revenue growth strategy across all market segments. She will lead the company's efforts in client acquisition, client management, an
MultiPlan Corporation (NYSE:MPLN) ("MultiPlan" or the "Company"), a leading provider of technology and data-enabled cost management, payment, and revenue integrity solutions to the U.S. health care industry, is honored to announce it has been named in the 2024 Fortune Best Workplaces in Health Care™ List. based on its 2023-2024 Great Place to Work® Certification™ results. This is the second time MultiPlan has been named in the Best Workplaces in Health Care list. Earning a spot means that MultiPlan is one of the best companies to work for in the country. The Best Workplaces in Health Care list is based on analysis of survey responses from over 185,000 employees from Great Place To Work Cer
MultiPlan Corporation ("MultiPlan" or the "Company") (NYSE:MPLN), a leading value-added provider of data analytics and technology-enabled end-to-end cost management, as well as payment and revenue integrity solutions to the U.S. healthcare industry, announced today its CFO transition plan and named Doug Garis as EVP and CFO, effective August 5, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240731993142/en/Doug Garis named EVP and CFO of MultiPlan (Photo: Business Wire) Jim Head, who has served as EVP and CFO of MultiPlan since November 2021, will transition to a Strategic Advisor role to the Company through the end of the
Piper Sandler initiated coverage of MultiPlan with a rating of Neutral and set a new price target of $2.00
Citigroup downgraded MultiPlan from Buy to Neutral and set a new price target of $2.00 from $3.00 previously
Goldman initiated coverage of MultiPlan with a rating of Neutral and set a new price target of $6.50
8-K - MultiPlan Corp (0001793229) (Filer)
8-K - MultiPlan Corp (0001793229) (Filer)
8-K - MultiPlan Corp (0001793229) (Filer)
SC 13G/A - MultiPlan Corp (0001793229) (Subject)
SC 13G/A - MultiPlan Corp (0001793229) (Subject)
SC 13G/A - MultiPlan Corp (0001793229) (Subject)
4 - MultiPlan Corp (0001793229) (Issuer)
3 - MultiPlan Corp (0001793229) (Issuer)
3 - MultiPlan Corp (0001793229) (Issuer)
Piper Sandler analyst Jessica Tassan initiates coverage on MultiPlan (NYSE:MPLN) with a Neutral rating and announces Price Target of $2.
Gainers Anitra (AMEX:AZTR) shares increased by 6.5% to $0.18 during Wednesday's after-market session. The market value of their outstanding shares is at $5.1 million. Oragenics (AMEX:OGEN) shares increased by 4.24% to $2.04. The market value of their outstanding shares is at $9.1 million. PACS Group (NYSE:PACS) shares rose 3.95% to $31.52. The market value of their outstanding shares is at $4.8 billion. MultiPlan (NYSE:MPLN) shares moved upwards by 3.49% to $0.45. The market value of their outstanding shares is at $290.3 million. Nanoviricides (AMEX:NNVC) stock moved upwards by 2.01% to $2.48. The market value of their outstanding shares is at $29.2 million. Calidi Biotherapeutics (AME
– Q3 2024 Revenues of $230.5 million, Net Loss of $391.5 million (including a $361.6 million impairment of goodwill and indefinite-lived intangibles), and Adjusted EBITDA of $141.6 million – Identified potential medical cost savings of approximately $6.4 billion in Q3 2024, up 10% from Q3 2023 and up 3% from Q2 2024 MultiPlan Corporation ("MultiPlan" or the "Company") (NYSE:MPLN), a leading provider of data-driven cost management solutions that deliver transparency and promote fairness, quality and affordability to the U.S. healthcare industry, today reported financial results for the third quarter ended September 30, 2024 and updated its full-year 2024 guidance. CEO Travis Dalton said,
MultiPlan Corporation ("MultiPlan" or the "Company") (NYSE:MPLN), a leading provider of data-driven cost management solutions that deliver transparency and promote fairness, quality and affordability to the U.S. healthcare industry, announced today that it will release its third quarter 2024 financial results on Tuesday, November 5, 2024, and hold its conference call that morning at 8:30 am Eastern Time. To join the conference call, please pre-register using the following link at least 10 minutes before the call begins: https://www.netroadshow.com/events/login?show=95da760a&confId=71678. Upon registration, you will receive an email with the conference dial-in details and a unique access co
– Q2 2024 Revenues of $233.5 million, Net Loss of $576.7 million (including a $553.7 million impairment of goodwill), and Adjusted EBITDA of $146.7 million – Identified potential medical cost savings of approximately $6.2 billion in Q2 2024, up 9% from Q2 2023 and up 8% from Q1 2024 – CFO transition plan announced MultiPlan Corporation ("MultiPlan" or the "Company") (NYSE:MPLN), a leading value-added provider of data analytics and technology-enabled end-to-end cost management, payment and revenue integrity solutions to the U.S. healthcare industry, today reported financial results for the second quarter ended June 30, 2024 and updated its full-year 2024 guidance. CEO Travis Dalton s